Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

The 10 Richest People on Wall Street and How to Invest in Them

By Thomas Niel, InvestorPlace Contributor

Knowing what stocks the richest people on Wall Street currently own could help you find potential winners for your portfolio.

Lucid Group Stock Has More to Fall, So Bulls Should Exercise Patience

By Thomas Niel, InvestorPlace Contributor

The valuation of LCID today at $20 per share still prices-in its long-term, and then some, as was the case back in July, when it traded for around $27 per share. But if the issues mentioned above sink it further towards its SPAC offering price of $10 per share? Investors bullish it's still a "Tesla killer" in the making may be able to buy at a price where the odds are more in their favor.

Shiba Inu Is a Crypto Gamble That Can’t Be Handicapped

By Thomas Niel, InvestorPlace Contributor

The only thing that's going to send Shiba Inu dramatically higher? A repeat of the speculative frenzy seen earlier this year. But given it's tough to handicap when that next happens (if at all), steer clear of this situation.

7 Penny Stocks Waiting on the FDA for Rocket Fuel

By Thomas Niel, InvestorPlace Contributor

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks.

Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy

By Thomas Niel, InvestorPlace Contributor

Simufilam's eventual approval is still uncertain. Its fading popularity among the Reddit set is a concern as well. Even after it 57%+ price haircut, approach SAVA stock cautiously.

Load More